The United States Food and Drug Administration has granted Marshall Edwards, Inc. an investigative new drug (IND) indication for triphendiol (NV-196).
Triphendiol is a chemosensitizing agent that is thought to depolarize mitochrondria and downregulate XIAP. It has also demonstrated broad cytostatic and cytotoxic properties against human cancer cells in vitro.
The IND indication is for triphendiol to be used in combination with Gemzar® (gemcitabine) for the treatment of unresectable, locally advanced, or metastatic pancreatic and bile duct cancers. The IND will enable a Phase IB study of triphendiol to proceed.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
